Nothing Special   »   [go: up one dir, main page]

HUE047238T2 - Szérumalbuminhoz kötõdõ fehérjék - Google Patents

Szérumalbuminhoz kötõdõ fehérjék

Info

Publication number
HUE047238T2
HUE047238T2 HUE12727658A HUE12727658A HUE047238T2 HU E047238 T2 HUE047238 T2 HU E047238T2 HU E12727658 A HUE12727658 A HU E12727658A HU E12727658 A HUE12727658 A HU E12727658A HU E047238 T2 HUE047238 T2 HU E047238T2
Authority
HU
Hungary
Prior art keywords
serum albumin
binding proteins
albumin binding
proteins
serum
Prior art date
Application number
HUE12727658A
Other languages
English (en)
Inventor
Bruno Dombrecht
Peter Schotte
Cedric Jozef Neotere Ververken
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HUE047238T2 publication Critical patent/HUE047238T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE12727658A 2011-06-23 2012-06-14 Szérumalbuminhoz kötõdõ fehérjék HUE047238T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23

Publications (1)

Publication Number Publication Date
HUE047238T2 true HUE047238T2 (hu) 2020-04-28

Family

ID=46298413

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12727658A HUE047238T2 (hu) 2011-06-23 2012-06-14 Szérumalbuminhoz kötõdõ fehérjék

Country Status (17)

Country Link
US (2) US9573992B2 (hu)
EP (3) EP2723771B1 (hu)
JP (3) JP6324887B2 (hu)
CN (2) CN106046168A (hu)
AU (1) AU2012271974B2 (hu)
CA (1) CA2839779C (hu)
CY (1) CY1122691T1 (hu)
DK (1) DK2723771T3 (hu)
ES (1) ES2759936T3 (hu)
HR (2) HRP20170535T4 (hu)
HU (1) HUE047238T2 (hu)
IN (1) IN2014CN00414A (hu)
LT (1) LT2723771T (hu)
PL (1) PL2723771T3 (hu)
PT (1) PT2723771T (hu)
SI (1) SI2723771T1 (hu)
WO (1) WO2012175400A1 (hu)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) * 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
EP2723769B2 (en) 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN103889451B (zh) * 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
ES2900852T3 (es) 2014-05-16 2022-03-18 Ablynx Nv Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
PL3233910T3 (pl) 2014-12-19 2020-06-01 Ablynx N.V. Dimery nanociał połączone cysteiną
WO2016120843A1 (en) 2015-01-29 2016-08-04 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
NO2768984T3 (hu) 2015-11-12 2018-06-09
SI3374392T1 (sl) 2015-11-13 2022-04-29 Ablynx Nv Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin
JP6768800B2 (ja) 2015-11-18 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Ctla4結合性物質
CN109071639B (zh) 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
AU2016357460B2 (en) * 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
EP3932945A1 (en) 2015-11-27 2022-01-05 Ablynx NV Polypeptides inhibiting cd40l
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201810327XA (en) * 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
US20190195866A1 (en) 2016-06-23 2019-06-27 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
CN117700549A (zh) 2016-11-16 2024-03-15 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
JP7417421B2 (ja) 2016-12-07 2024-01-18 アブリンクス エン.ヴェー. 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
CN110191896B (zh) 2017-01-17 2023-09-29 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
EP4442708A2 (en) * 2017-01-17 2024-10-09 Ablynx NV Improved serum albumin binders
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MX2019011702A (es) 2017-03-31 2019-11-01 Ablynx Nv Ensayos de inmunogenicidad mejorados.
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
CN111465612B (zh) 2017-10-13 2024-08-27 哈普恩治疗公司 B细胞成熟抗原结合蛋白
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US20200392512A1 (en) * 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
IL297931B1 (en) 2018-09-25 2024-11-01 Harpoon Therapeutics Inc DLL3 binding proteins and methods of use
CN110964107B (zh) * 2018-09-30 2022-08-09 苏州康宁杰瑞生物科技有限公司 Met结合分子、其组合和用途
CN111138537B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 一种抗人血清白蛋白抗体片段、制备方法和应用
CN111138536B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 抗人血清白蛋白单域抗体的制备及其应用
US20220227850A1 (en) * 2019-05-15 2022-07-21 Crescendo Biologics Limited Binding molecules
CN114981300A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
EP4069293A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
BR112022010223A2 (pt) 2019-12-09 2022-09-06 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp)
CN110988361B (zh) * 2019-12-13 2020-09-18 山东民康生物科技有限公司 人血清白蛋白去除试剂盒
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
AU2021246890A1 (en) 2020-03-30 2022-12-01 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CN112142846B (zh) * 2020-10-10 2022-07-08 西北大学 Aox特异性抗体组合及其制备方法和用途
EP4237438A1 (en) * 2020-10-27 2023-09-06 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
AU2021402090A1 (en) 2020-12-18 2023-08-03 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
JP2023553694A (ja) 2020-12-18 2023-12-25 アブリンクス エン.ヴェー. IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2022129560A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
CN117586423A (zh) * 2021-07-14 2024-02-23 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
CN118556077A (zh) * 2021-11-17 2024-08-27 南京再明医药有限公司 一种多特异性抗体及其药物用途
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
CN118139892A (zh) * 2022-01-14 2024-06-04 浙江道尔生物科技有限公司 一种三靶点抗肿瘤药物、其制备方法及其应用
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024153195A1 (en) * 2023-01-18 2024-07-25 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of fusion polypeptides and methods of uses thereof
US20240368250A1 (en) * 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024215940A1 (en) 2023-04-11 2024-10-17 Visterra, Inc. Apelin receptor agonists and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
NZ540195A (en) 2002-11-08 2009-01-31 Ablynx Nv Stabilized single domain antibodies
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
SG184709A1 (en) 2005-05-18 2012-10-30 Ablynx Nv Improved nanobodies™ against tumor necrosis factor-alpha
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
CA2640066A1 (en) 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
TW200815470A (en) * 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CA2658612C (en) 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP2010505435A (ja) * 2006-10-11 2010-02-25 アブリンクス エン.ヴェー. 本質的にpHに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US7867497B2 (en) 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
US9193780B2 (en) 2008-06-05 2015-11-24 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
MX2011010151A (es) * 2009-03-27 2011-12-14 Glaxo Group Ltd Fusiones y conjugados de farmaco.
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
KR20120102125A (ko) 2009-12-18 2012-09-17 사노피 Gpvi에 대한 신규한 길항제 항체 및 그의 fab 단편 및 그의 용도
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) * 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723769B2 (en) 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2987806A3 (en) 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met

Also Published As

Publication number Publication date
DK2723771T3 (da) 2019-12-02
US20140228546A1 (en) 2014-08-14
CY1122691T1 (el) 2021-03-12
JP7304375B2 (ja) 2023-07-06
JP6843090B2 (ja) 2021-03-17
CA2839779A1 (en) 2012-12-27
US20170210789A1 (en) 2017-07-27
CN103619878A (zh) 2014-03-05
PT2723771T (pt) 2019-12-11
AU2012271974B2 (en) 2017-01-12
EP4218933A1 (en) 2023-08-02
ES2759936T3 (es) 2020-05-12
EP2723771A1 (en) 2014-04-30
JP6324887B2 (ja) 2018-05-16
WO2012175400A1 (en) 2012-12-27
HRP20170535T4 (hr) 2022-08-19
EP3466972A1 (en) 2019-04-10
HRP20192160T1 (hr) 2020-02-21
CA2839779C (en) 2020-10-06
EP2723771B1 (en) 2019-09-11
CN106046168A (zh) 2016-10-26
LT2723771T (lt) 2019-12-10
IN2014CN00414A (hu) 2015-04-03
HRP20170535T1 (hr) 2017-06-16
CN103619878B (zh) 2016-10-26
PL2723771T3 (pl) 2020-04-30
US9573992B2 (en) 2017-02-21
JP2021088585A (ja) 2021-06-10
JP2018127478A (ja) 2018-08-16
AU2012271974A1 (en) 2013-12-12
SI2723771T1 (sl) 2019-12-31
JP2014520129A (ja) 2014-08-21

Similar Documents

Publication Publication Date Title
HUE047238T2 (hu) Szérumalbuminhoz kötõdõ fehérjék
PL2643349T3 (pl) Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
ZA201209091B (en) Serum albumin binding molecules
EP2681239B8 (en) Antigen binding proteins
SG11201401649VA (en) Albumin binding antibodies and binding fragments thereof
HK1199042A1 (en) Cd27l antigen binding proteins cd27l
HK1202444A1 (en) Il-1 binding proteins il-1
HK1207656A1 (en) Albumin binding polypeptide
HK1198832A1 (en) Fn14 binding proteins and uses thereof fn14
HRP20181666T1 (hr) Proteini koji se vežu na antigene, specifični za komponentu p serumskog amiloida
PL2912054T3 (pl) Polipeptyd wiążący albuminę
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
IL226157A0 (en) Antigen binding proteins
HK1203404A1 (en) Serum amyloid p-antibody fusion proteins p-